IRVINE, Calif., June 25, 2009 (GLOBE NEWSWIRE) -- SectorWatch.biz announces the availability of an important new commentary of interest to investors in Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) and other high-performance fiber equities making news and driving markets today. Investors can view our free commentaries at: www.SectorWatch.biz -- in association with FiSpace.net, a dynamic social networking site for investors.
For decades scientists have been fascinated by the silk fibers that make up certain spider webs. In fact, spider silk is one of the strongest and most resilient fibers known to man, making it a potential "super fiber" for a host of ballistic resistant, medical, and industrial applications. We are told that spider silk is about five times stronger than steel and twice as strong as DuPont's market-leading Kevlar(r) on a pound-for-pound basis. Spider silk can also stretch about 30% longer than its original length without breaking, making its threads extremely resilient.
Kraig Biocraft Laboratories is developing a way of inserting spider silk DNA directly into silkworms allowing silkworms to produce the proteins for spider silk. Kraig is working in cooperation with University of Notre Dame scientists and laboratories to create new polymers with potentially broad applications for consumers and industry in the $92 billion marketplace for high performance fibers.
A comprehensive report on KBLB is available FREE at this link: http://www.kraiglabs.com/pdf/KBLBR%20report%201.26.2009.pdf
SectorWatch.biz is powered by Market Pathways, a leader in the representation of smallcap equities for nearly thirty years. Call us at the number below to have your company featured in our publications: SectorWatch.biz and StockUpTicks.com.
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SectorWatch.biz is a property of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies have not always approved the statements made in this report. This report is neither a solicitation to buy nor an offer to sell securities but is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor, analyst or licensed broker dealer and this report is not investment advice. J.A. Knepp CRD#2849651. MP has been paid $1,500 by The DreamTeam Group, LLC on behalf of Kraig Biocraft Laboratories for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.